1/85
Looks like no tags are added yet.
Diabetic Ketoacidosis (DKA) Pathophysiology
Absolute lack of insulin causing severe hyperglycemia (> 250 mg/dL), lipolysis, ketone accumulation, and high anion gap metabolic acidosis
Hyperosmolar Hyperglycemic State (HHS) Pathophysiology
Relative lack of insulin preventing lipolysis/ketosis but causing extreme hyperglycemia (> 600 mg/dL), massive dehydration (> 9 L deficit), and hyperosmolality
DKA Diagnostic Blood Glucose Level
Typically greater than 250 mg/dL
HHS Diagnostic Blood Glucose Level
Typically greater than 600 mg/dL
DKA Arterial/Venous pH Target
Arterial or venous pH less than 7
30 (mild: 7
25-7
30, moderate: 7
00-7
24, severe: < 7
00)
DKA Serum Bicarbonate Level
Serum bicarbonate (HCO3) less than or equal to 15 mEq/L (severe: < 10 mEq/L)
DKA Anion Gap Threshold
Anion gap greater than 10 mEq/L, indicating high anion gap metabolic acidosis
HHS Diagnostic Serum Osmolality
Serum osmolality greater than 320 mOsm/kg H2O
DKA Primary Clinical Triad
Hyperglycemia (> 250 mg/dL), metabolic acidosis (pH < 7
3, HCO3 ≤ 15 mEq/L), and blood/urine ketosis
Gold Standard DKA Ketone Diagnostic Test
Point-of-care quantitative blood beta-hydroxybutyrate test (superior to urine ketone tests)
Kussmaul Respirations
Deep, rapid, labored breathing pattern in DKA compensating for metabolic acidosis by blowing off carbon dioxide
Fruity-Smelling Breath
Acetone odor on the breath resulting from volatile ketone accumulation in DKA
HHS Neurological Manifestations
Severe lethargy, stupor, and coma driven by extreme serum hyperosmolality (> 320 mOsm/kg) and cerebral dehydration
DKA Total Body Water Deficit
Approximately 6 liters
HHS Total Body Water Deficit
Exceeds 9 liters, creating severe hyperviscosity and high thromboembolic risk
HHS Mortality Rate vs DKA
HHS mortality is up to 20% (10 times higher than DKA) due to older age, severe dehydration, and pre-existing comorbidities
First Priority Intervention for DKA and HHS
Isotonic fluid resuscitation with 0
9% Normal Saline at 15 to 20 mL/kg/hr during the first hour to restore intravascular volume
Second Hour IV Fluid Selection for DKA/HHS
Guided by corrected serum sodium
45% Normal Saline if corrected sodium is normal or high
Critical Potassium Safety Rule Before Insulin
Verify serum potassium is 3
3 mEq/L or higher before starting IV regular insulin infusion
Action if Potassium is Less Than 3
3 mEq/L
Hold insulin infusion immediately and administer IV potassium replacement until serum K+ exceeds 3
3 mEq/L to prevent fatal dysrhythmias
Target Serum Potassium Range During Treatment
Maintain serum potassium between 4
0 and 5
0 mEq/L by adding 20 to 30 mEq K+ per liter of IV fluid when K+ is 3
3 to 5
2 mEq/L
Initial Continuous IV Insulin Titration Goal
Titrate IV regular insulin infusion to achieve a steady blood glucose drop of 50 to 70 mg/dL per hour
Critical Care Blood Glucose Target
Maintain capillary blood glucose between 140 and 180 mg/dL in critically ill clients
Indication to Add Dextrose to IV Fluids
Add 5% Dextrose (e
g
, D5 0
45% NS) when blood glucose drops below 200 mg/dL in DKA or 250 mg/dL in HHS
Rationale for Adding Dextrose
Prevents rapid hypoglycemia and cerebral edema while allowing continuous IV insulin to safely clear ketones and resolve acidosis
DKA Resolution Criteria
Blood glucose < 200 mg/dL AND at least two of the following: pH > 7
3, serum HCO3 ≥ 15 mEq/L, or anion gap ≤ 12 mEq/L
HHS Resolution Criteria
Serum osmolality < 320 mOsm/kg and recovery of baseline mental status
Subcutaneous Insulin Transition 2-Hour Overlap Rule
Overlap IV regular insulin with the first subcutaneous insulin injection by at least 2 hours to prevent an insulin gap and rebound DKA
Sodium Bicarbonate Indication in DKA
Reserved strictly for severe metabolic acidosis with pH less than 6
9
routine use is avoided to prevent hypokalemia and paradoxical ketosis
Cause of False High Initial Potassium in DKA
Insulin deficiency and metabolic acidosis shift potassium out of cells into the blood, masking total-body potassium depletion
Arginine Vasopressin Disorder (AVP Disorder / DI) Pathophysiology
Inability to concentrate urine due to inadequate ADH secretion (Central AVP-D) or renal tubule resistance to ADH (Nephrogenic AVP-R)
Central AVP Disorder (AVP-D) Etiology
Caused by posterior pituitary/hypothalamic damage from neurosurgery (20% post-op prevalence), TBI, head trauma, brain tumors, or CNS infection
Nephrogenic AVP Disorder (AVP-R) Etiology
Caused by renal tubule resistance to ADH, most commonly triggered by lithium toxicity, hypercalcemia, hypokalemia, or amphotericin B
AVP Disorder Serum Profile
Elevated serum sodium (> 145 mEq/L), elevated serum osmolality (> 300 mOsm/kg), and elevated BUN/creatinine due to severe dehydration
AVP Disorder Urine Profile
High urine output (> 3 L/day), low urine specific gravity (< 1
005), low urine osmolality (< 300 mOsm/kg), and low urinary sodium (< 40 mEq/day)
Hallmark Clinical Triad of AVP Disorder
Polyuria (> 3 L/day of dilute, clear urine), polydipsia (extreme thirst), and nocturia
Water Deprivation Test Purpose
Diagnostic gold standard that confirms AVP disorder when urine osmolality remains < 300 mOsm/kg despite fluid restriction
Desmopressin Challenge in Water Deprivation Test
Differentiates Central AVP-D (urine osmolality surges to > 750 mOsm/kg) from Nephrogenic AVP-R (no increase in urine osmolality)
Primary Hypotonic IV Fluid for AVP Disorder
Dextrose 5% in Water (D5W) or 0
45% Normal Saline administered at a max rate of 500 to 750 mL/hour to replace water loss
Safe Sodium Reduction Rate in Hypernatremia
Lower serum sodium gradually by no more than 0
5 mEq/L per hour to prevent rapid fluid shifts and cerebral edema
Desmopressin (DDAVP) Indication
First-line synthetic vasopressin analog for Central AVP-D that stimulates V2 renal receptors to reduce urine output
Desmopressin Medication Safety Warning
Over-retention of water causes dilutional hyponatremia and cerebral edema
Thiazide Diuretics Indication in Nephrogenic AVP-R
Hydrochlorothiazide paradoxically decreases urine volume by causing mild volume depletion and increasing proximal tubule reabsorption
Dietary Modification for AVP Disorder
A diet low in protein and low in sodium to decrease renal solute load and reduce total urine output
SIADH Pathophysiology
Unsuppressed release of antidiuretic hormone (ADH) forcing kidneys to reabsorb excess water, diluting blood and causing euvolemic hyponatremia
Most Common Malignancy Triggering SIADH
Small cell lung cancer (ectopic ADH production)
Common Drug Classes Causing SIADH
SSRIs (especially in adults > 65 years), chemotherapeutic agents (cisplatin), carbamazepine, and excessive desmopressin
SIADH Euvolemic Water Retention Characteristic
Excess water is distributed evenly across body compartments without expanding intravascular volume enough to cause hypertension, JVD, or peripheral edema
SIADH Serum Profile
Low serum sodium (< 135 mEq/L) and low serum osmolality (< 285 mOsm/kg H2O) indicating blood dilution
SIADH Urine Profile
Concentrated urine with high urine specific gravity (> 1
030), high urine osmolality (> 100 mOsm/kg), and high 24-hour urine sodium (> 220 mEq/day)
Mild-to-Moderate SIADH Serum Sodium Range
120 to 125 mEq/L presenting with nausea, anorexia, fatigue, headache, muscle cramps, and decreased urine output
Severe SIADH Neurological Red Flags
Serum sodium less than 120 mEq/L causing severe cerebral edema, hyporeflexia, muscle tremors, seizures, obtundation, and coma
SIADH Respiratory Failure Critical Threshold
Serum sodium dropping below 115 mEq/L creates an immediate risk for respiratory arrest
First-Line Non-Pharmacological SIADH Intervention
Strict fluid restriction to 800-1,000 mL/day to reverse dilutional hyponatremia
Hypertonic Saline Indication in SIADH
3% Normal Saline IV bolus (100-150 mL) via central line reserved for severe symptomatic hyponatremia (Na < 120 mEq/L)
Osmotic Demyelination Syndrome (ODS)
Irreversible brainstem demyelination caused by correcting hyponatremia too rapidly
5-1 mEq/L/hr (max 8 mEq/L in 24hr)
Tolvaptan (Samsca) Mechanism and Caution
Oral V2 vasopressin receptor antagonist promoting free water excretion
Conivaptan (Vaprisol) Administration
Continuous IV vasopressin receptor antagonist administered via central line for 2 to 4 days to promote aquaresis in hospitalized SIADH
Furosemide (Lasix) Role in SIADH
Loop diuretic given alongside fluid restriction/saline to increase free water excretion and lower urine osmolality
Seizure Precautions for SIADH
Padded side rails, functioning suction at bedside, dim room lighting, and minimized environmental stimulation for clients with Na < 120 mEq/L